A150 An Intensive 52-week Nutritional, Exercise and Behavior Modification Program: Comparison With or Without the Elipse Intragastric Balloon

Raftopoulos, Yannis; Davidson, Elana; Robert, Karen; Chapin, Kristen; Chiapperino, Marissa; Pasdera, Lindsay; Tsechpenakis, Anastasios

doi:10.1016/j.soard.2019.08.096

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ten studies reported 6 month %TBWL outcomes, and in 9 of these studies IGB was associated with greater %TBWL than lifestyle modification (range of 7.6–14.1% compared to 3.3–6.7% with lifestyle modification). Six studies reported 12 month %TBWL outcomes, and in five of these studies IGB was associated with greater %TBWL (range of 7.5–14.0% after IGB compared to 3.1–7.9% with lifestyle modification [ 7 – 9 , 12 , 14 , 15 ]). The 4 RCTs reporting %TBWL at 12 months were pooled into a meta-analysis, with a random effect pooled estimate of 4.1% TBWL (95% CI, 3.0%–5.3%).…”

Section: Resultsmentioning

confidence: 99%

Endoscopic therapies for patients with obesity: a systematic review and meta-analysis

Weitzner,

Phan,

Begashaw

et al. 2023

Surg Endosc

View full text Add to dashboard Cite

Background Obesity is a major threat to public health and traditional bariatric surgery continues to have low utilization. Endoscopic treatments for obesity have emerged that offer less risk, but questions remain regarding efficacy, durability, and safety. We compared the efficacy of endoscopic bariatric procedures as compared to other existing treatments. Methods A literature search of Embase, Cochrane Central, and Pubmed was conducted from January 1, 2014 to December 7, 2021, including endoscopic bariatric therapies that were FDA or CE approved at the time of search to non-endoscopic treatments. Thirty-seven studies involving 15,639 patients were included. Primary outcomes included % total body weight loss (%TBWL), % excess body weight loss (%EBWL), and adverse events. Secondary outcomes included quality of life data and differences in hemoglobin A1C levels. Strength of clinical trial and observational data were graded according to the Cochrane methods. Results Intragastric balloons achieved greater %TBWL with a range of 7.6–14.1% compared to 3.3–6.7% with lifestyle modification at 6 months, and 7.5–14.0% compared to 3.1–7.9%, respectively, at 12 months. When endoscopic sleeve gastroplasty (ESG) was compared to laparoscopic sleeve gastrectomy (LSG), ESG had less %TBWL at 4.7–14.4% compared to 18.8–26.5% after LSG at 6 months, and 4.5–18.6% as compared to 28.4–29.3%, respectively, at 12 months. For the AspireAssist, there was greater %TBWL with aspiration therapy compared to lifestyle modification at 12 months, 12.1–18.3% TBWL versus 3.5–5.9% TBWL, respectively. All endoscopic interventions had higher adverse events rates compared to lifestyle modification. Conclusion This review is the first to evaluate various endoscopic bariatric therapies using only RCTs and observational studies for evaluation of weight loss compared with conservative management, lifestyle modification, and bariatric surgery. Endoscopic therapies result in greater weight loss compared to lifestyle modification, but not as much as bariatric surgery. Endoscopic therapies may be beneficial as an alternative to bariatric surgery.

show abstract